Ninja Reports

Ninja Reports

Share this post

Ninja Reports
Ninja Reports
MDGL - Earnings Preview

MDGL - Earnings Preview

What to expect from MDGL in Nov

Investing Ninja's avatar
Investing Ninja
Oct 16, 2024
∙ Paid
1

Share this post

Ninja Reports
Ninja Reports
MDGL - Earnings Preview
Share

Madrigal will report Q3 earnings sometime in November, and all eyes will be on resmetirom sales.

Q2 sales were $14.6M and surpassed low initial launch expectations. There were concerns about payor restrictions, Madrigal’s ability to reach the appropriate physicians and biopsy requirements. Some of those fears were allayed in Q2 and now the focus turns to sales ramp up.

Expectations are still modest, with the average analyst forecast at $33M.

Given that resmetirom had 2000 patients on drug, and has increased payor coverage recently, we think $50M is likely.

Our revenue calculation details are below:

Keep reading with a 7-day free trial

Subscribe to Ninja Reports to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Healthcare Ninja
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share